Protocols
6 protocol(s) meet the specified criteria
PI: Weiss, Jared
Protocol No.TitleStatus
A8081001Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGRF Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer Open
LCCC1621Multimodality Therapy with Induction Carboplatin/nab-Paclitaxel/Durvalumab (MEDI4736) Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Open
LCCC1725A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab together with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Open
LOXO-RET-17001A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer and Other Tumors with Increased RET ActivityOpen
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
NCI9903A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase InhibitorOpen